Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

20171,684 citationsJournal Articlebronze Open Access

Authors

William J. Sandborn · University of California, San Diego

Chinyu Su · Pfizer (United States)

Bruce E. Sands · Icahn School of Medicine at Mount Sinai

Geert D’Haens · Academic Medical Center

Séverine Vermeire · KU Leuven

Stefan Schreiber · University Hospital Schleswig-Holstein

Silvio Danese

Abstract

In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo. (Funded by Pfizer; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain ClinicalTrials.gov numbers, NCT01465763 , NCT01458951 , and NCT01458574 , respectively.).

Topics & Keywords

Inflammatory Bowel Disease Tuberculosis Research and Epidemiology Systemic Lupus Erythematosus Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 376, Issue 18, pp. 1723-1736

DOI: 10.1056/nejmoa1606910

Field-Weighted Citation Impact: 123.10